Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MGTA

DatePrice TargetRatingAnalyst
8/25/2022$2.00Buy → Neutral
Goldman
1/24/2022$13.00 → $6.00Buy
B. Riley Securities
1/6/2022$7.00 → $8.00Neutral → Buy
Goldman Sachs
8/20/2021$7.00Neutral
Goldman
8/3/2021$16.00 → $7.00Overweight → Neutral
JP Morgan
7/22/2021$21.00 → $19.00Buy
B. Riley Securities
6/29/2021$20.00Overweight
Cantor Fitzgerald
More analyst ratings

$MGTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

    CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the "combined company." Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for th

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

    Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus' new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications Companies will host a joint webcast today, May 3, 2023 at 8:30 a.m. ET

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

    CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MGTA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MGTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MGTA
SEC Filings

See more

$MGTA
Leadership Updates

Live Leadership Updates

See more
  • Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

    CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company's R&D Committee and Nominating and Corporate Governance Committee.  "We are delighted to welcome Mike Vasconcelles to the Magenta board," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Dr. Vasconcelles brings deep experience in research, medical operations, clinical trial design

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

    Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug development and has been involved with the development of more than 20 drug candidates, including regulatory submissions leading to multiple drug approvals in the United States and Europe. "As Magenta continues to advance our clinical and pr

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

    Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. "Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development." As Chief

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Financials

Live finance-specific insights

See more
  • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

    CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

    – MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment – – CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing – – MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 – – Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 – CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NAS

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

    CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting. The oral presentation at ASH, entitled "MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more